Why the study?
Patients with intermediate-high risk PE may be candidates for thrombolytic therapy, but clinical outcomes comparing low-dose prolonged thrombolytic therapy with unfractionated heparin needed evaluation.
Does low-dose, slow-infusion thrombolytic therapy reduce the composite of death, hemodynamic decompensation, and severe bleeding in patients with intermediate-high risk pulmonary embolism compared to unfractionated heparin?
Population
83 intermediate-high risk PE patients
Comparison
Low-dose, slow-infusion thrombolytic therapy vs unfractionated heparin
Design
Retrospective study
Authors
Loading...
Should not yet change practice in intermediate-high risk PE; leaves open benefit of low-dose thrombolysis pending randomized trials.
Does low-dose, slow-infusion thrombolytic therapy reduce the composite of death, hemodynamic decompensation, and severe bleeding in patients with intermediate-high risk pulmonary embolism compared to unfractionated heparin?
A low-dose, slow-infusion thrombolytic regimen in intermediate-high risk pulmonary embolism significantly reduced hemodynamic decompensation and pulmonary hypertension compared to unfractionated heparin, without a significant increase in bleeding complications.
Özgür Sürgit (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: